Methods of producing multispecific antibodies against CD40 and CD137
Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
1. A method of producing a multispecific antibody, comprising:
a) providing a first antibody comprising two first antigen-binding regions and a first Fc region,
wherein each first antigen-binding region is capable of binding to CD40 and comprises three heavy chain CDRs comprising amino acid sequences of SEQ ID NO:1 (HCDR1), SEQ ID NO:2 (HCDR2), and SEQ ID NO:3 (HCDR3); and three light chain CDRs comprising amino acid sequences of SEQ ID NO:4 (LCDR1), YTS (LCDR2), and SEQ ID NO:5 (LCDR3); and
wherein the first Fc region comprises a first CH3 region;
b) providing a second antibody comprising two second antigen-binding regions and a second Fc region,
wherein each second antigen-binding region is capable of binding to CD137 and comprises:
i) three heavy chain CDRs comprising amino acid sequences of SEQ ID NO:64 (HCDR1), SEQ ID NO:65 (HCDR2), and SEQ ID NO:66 (HCDR3); and three light chain CDRs comprising amino acid sequences of SEQ ID NO:67 (LCDR1), GAS (LCDR2), and SEQ ID NO:68 (LCDR3); or
ii) three heavy chain CDRs comprising amino acid sequences of SEQ ID NO:36 (HCDR1), SEQ ID NO:37 (HCDR2), and SEQ ID NO:38 (HCDR3); and three light chain CDRs comprising amino acid sequences of SEQ ID NO:39 (LCDR1), SAS (LCDR2), and SEQ ID NO:40 (LCDR3); and
wherein the second Fc region comprises a second CH3 region; and wherein the amino acid sequences of the first and second CH3 regions are different, and wherein the heterodimeric interaction between the first and second CH3 regions has a lower dissociation equilibrium constant (K D ) than each of the homodimeric interactions of the first and second CH3 regions;
c) incubating the first antibody together with the second antibody under reducing conditions; and
d) isolating a CD40xCD137 antibody.
2. The method of claim 1 , wherein each of the first antigen-binding regions comprises: (i) a heavy chain variable region (VH) comprising an amino acid sequence having at least 90% identity to SEQ ID NO:117 or SEQ ID NO:6; and/or (ii) a light chain variable region (VL) comprising an amino acid sequence having at least 90% identity to SEQ ID NO:121 or SEQ ID NO:7.
3. The method of claim 1 , wherein each of the first antigen-binding regions comprises a VH comprising an amino acid sequence of SEQ ID NO:117; and a VL comprising an amino acid sequence of SEQ ID NO:121.
4. The method of claim 1 , wherein each of the second antigen-binding regions comprises three heavy chain CDRs comprising amino acid sequences of SEQ ID NO:64 (HCDR1), SEQ ID NO:65 (HCDR2), and SEQ ID NO:66 (HCDR3); and three light chain CDRs comprising amino acid sequences of SEQ ID NO:67 (LCDR1), GAS (LCDR2), and SEQ ID NO:68 (LCDR3).
5. The method of claim 1 , wherein each of the second antigen-binding regions comprises a VH comprising an amino acid sequence having at least 90% identity to SEQ ID NO:123 or SEQ ID NO:69.
6. The method of claim 1 , wherein each of the second antigen-binding regions comprises a VL comprising an amino acid sequence having at least 90% identity to SEQ ID NO:127 or SEQ ID NO:70.
7. The method of claim 1 , wherein each of the second antigen-binding regions comprises a VH comprising an amino acid sequence of SEQ ID NO:123; and a VL comprising an amino acid sequence of SEQ ID NO:127.
8. The method of claim 1 , wherein each of the second antigen-binding regions comprises three heavy chain CDRs comprising amino acid sequences of SEQ ID NO:36 (HCDR1), SEQ ID NO:37 (HCDR2), and SEQ ID NO:38 (HCDR3); and three light chain CDRs comprising amino acid sequences of SEQ ID NO:39 (LCDR1), SAS (LCDR2), and SEQ ID NO:40 (LCDR3).
9. The method of claim 1 , wherein each of the second antigen-binding regions comprises a VH comprising an amino acid sequence having at least 90% identity to SEQ ID NO:41.
10. The method of claim 1 , wherein each of the second antigen binding regions comprises a VL comprising an amino acid sequence having at least 90% identity to SEQ ID NO:42.
11. The method of claim 1 , wherein each of the second antigen-binding regions comprises a VH comprising an amino acid sequence of SEQ ID NO:41; and a VL comprising an amino acid sequence of SEQ ID NO:42.
12. The method of claim 1 , wherein the first and second Fc regions each comprise at least a hinge region, a CH2 region, and a CH3 region.
13. The method of claim 1 , wherein the first and second CH3 regions each comprise one or more asymmetrical amino acid mutations.
14. The method of claim 1 , wherein the first and second CH3 regions each comprise an amino acid substitution at one or more positions corresponding to EU index positions T366, L368, K370, D399, F405, Y407, and/or K409 in a human IgG1 heavy chain; and wherein the first and second heavy chains comprise amino acid substitutions at non-identical positions.
15. The method of claim 1 , wherein the first CH3 region comprises a leucine (L) at the position corresponding to EU index position F405 in a human IgG1 heavy chain, and the second CH3 region comprises an arginine (R) at the position corresponding to EU index position K409 in a human IgG1 heavy chain.
16. The method of claim 1 , wherein the first CH3 region comprises an arginine (R) at the position corresponding to EU index position K409 in a human IgG1 heavy chain, and the second CH3 region comprises a leucine (L) at the position corresponding to EU index position F405 in a human IgG1 heavy chain.
17. The method of claim 1 , wherein the first and second Fc regions each comprise a phenylalanine (F) and a glutamic acid (E) at positions corresponding to EU index positions L234 and L235 in a human IgG1 heavy chain, respectively.
18. The method of claim 1 , wherein the first and second Fc regions each comprise a phenylalanine (F), a glutamic acid (E), and an alanine (A) at positions corresponding to EU index positions L234, L235, and D265 in a human IgG1 heavy chain, respectively.
19. The method of claim 18 , wherein the first Fc region comprises a leucine (L) at the position corresponding to EU index position F405 in a human IgG1 heavy chain and the second Fc region comprises an arginine (R) at the position corresponding to EU index position K409 in a human IgG1 heavy chain.
20. The method of claim 18 , wherein the second Fc region comprises a leucine (L) at the position corresponding to EU index position F405 in a human IgG1 heavy chain and the first Fc region comprises an arginine (R) at the position corresponding to EU index position K409 in a human IgG1 heavy chain.